ES2078175A1 - Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones. - Google Patents

Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.

Info

Publication number
ES2078175A1
ES2078175A1 ES09302735A ES9302735A ES2078175A1 ES 2078175 A1 ES2078175 A1 ES 2078175A1 ES 09302735 A ES09302735 A ES 09302735A ES 9302735 A ES9302735 A ES 9302735A ES 2078175 A1 ES2078175 A1 ES 2078175A1
Authority
ES
Spain
Prior art keywords
agents
tobramycin
applications
pharmaceutical formulation
formulation containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09302735A
Other languages
English (en)
Other versions
ES2078175B1 (es
Inventor
Michael Van Wie Bergamini
Cabrera Antonio Lopez
Mas Jose Alberto Vallet
Laguens Carmen Oros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Cusi SA
Original Assignee
Laboratorios Cusi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Cusi SA filed Critical Laboratorios Cusi SA
Priority to ES09302735A priority Critical patent/ES2078175B1/es
Priority to EP94203756A priority patent/EP0661055A1/en
Priority to JP7000087A priority patent/JPH07309763A/ja
Publication of ES2078175A1 publication Critical patent/ES2078175A1/es
Application granted granted Critical
Publication of ES2078175B1 publication Critical patent/ES2078175B1/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMULACION FARMACEUTICA CONTENIENDO CLOBETASONA Y TOBRAMICINA Y SUS APLICACIONES. LA COMPOSICION COMPRENDE: 0,001-5,0 POR CIENTO DE CLOBETASONA O UN ISOMERO O UN DERIVADO O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES; 0,05-5,0 POR CIENTO DE TOBRAMICINA O UN ISOMERO O UN DERIVADO O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES; Y, OPCIONALMENTE, UNO O MAS INGREDIENTES SELECCIONADOS ENTRE AGENTES ISOTONIZANTES, AMORTIGUADORES DEL PH, VISCOSIZANTES, HUMECTANTES, QUELANTES, ANTIOXIDANTES, CONSERVADORES, SOLUBILIZANTES, ADEMAS DE UNO O VARIOS EXCIPIENTES ADECUADOS A LA FORMA DE PRESENTACION FARMACEUTICA DE LA FORMULACION. DICHA FORMULACION PRESENTA UN PH COMPRENDIDO ENTRE 4 Y 9. APLICACION PARA EL TRATAMIENTO DE LOS PROCESOS INFLAMATORIOS OCULARES Y OTICOS ACOMPAÑADOS DE INFECCION.
ES09302735A 1993-12-31 1993-12-31 Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones. Expired - Lifetime ES2078175B1 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ES09302735A ES2078175B1 (es) 1993-12-31 1993-12-31 Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.
EP94203756A EP0661055A1 (en) 1993-12-31 1994-12-23 Pharmaceutical formulation containing clobetasone and tobramycin and applications thereof
JP7000087A JPH07309763A (ja) 1993-12-31 1995-01-04 クロベタゾンおよびトブラマイシンを含有する医薬製剤とその応用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09302735A ES2078175B1 (es) 1993-12-31 1993-12-31 Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.

Publications (2)

Publication Number Publication Date
ES2078175A1 true ES2078175A1 (es) 1995-12-01
ES2078175B1 ES2078175B1 (es) 1996-10-16

Family

ID=8284085

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09302735A Expired - Lifetime ES2078175B1 (es) 1993-12-31 1993-12-31 Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.

Country Status (3)

Country Link
EP (1) EP0661055A1 (es)
JP (1) JPH07309763A (es)
ES (1) ES2078175B1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69526787T2 (de) * 1995-07-05 2002-12-05 Europ Community Luxemburg Luxe Biokompatibele und biodegradierbare Nanokapseln zur Absorption und Verabreichung von proteinischen Arzneimitteln
EP1020194A4 (en) * 1997-10-01 2003-05-21 Wakamoto Pharma Co Ltd OIL / WATER EMULSION COMPILATIONS
DK1214056T3 (da) 1999-09-24 2004-02-09 Alcon Inc Topiske suspensionsformuleringer indeholdende ciprofloxacin og dexamethason
FR2802097B1 (fr) * 1999-12-14 2002-12-13 Invest S Therapeutiques Essais Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication
WO2002007704A2 (en) 2000-07-26 2002-01-31 Alcon Universal Ltd. Improved process for manufacturing compositions containing ciprofloxacin and hydrocortisone
MXPA04002576A (es) 2001-09-21 2004-06-18 Alcon Inc Metodo para tratar infecciones del oido medio.
JP2006257080A (ja) * 2005-02-18 2006-09-28 Santen Pharmaceut Co Ltd ステロイド化合物の副作用軽減または回避方法
US20080166417A1 (en) * 2005-02-18 2008-07-10 Kazuhito Yamada Method of Relieving or Avoiding Side Effect of Steroid
KR101430760B1 (ko) 2005-10-18 2014-08-19 알러간, 인코포레이티드 후안부 조직으로 선택적으로 침투하는 글루코코르티코이드유도체를 사용한 안과 요법
JP2012506435A (ja) * 2008-10-21 2012-03-15 ギリアード サイエンシーズ， インコーポレイテッド 眼の感染症、耳の感染症、および皮膚の感染症の処置および予防のためのホスホマイシン／トブラマイシンの組み合わせ
MX2011007804A (es) * 2009-01-23 2011-12-06 Quadra Logic Tech Inc Suministro de liberación sostenida de uno o más agentes.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES362679A1 (es) * 1968-01-19 1971-02-01 Glaxo Lab Ltd Un procedimiento para la preparacion de nuevos esteroides anti-inflamatorios, de la serie del pregnano.
US4478822A (en) * 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
WO1989009057A1 (en) * 1988-03-09 1989-10-05 Alcon Laboratories, Inc. Combination of tobramycin and steroids for topical ophthalmic use
EP0343268A1 (en) * 1988-05-25 1989-11-29 Biogal Gyogyszergyar Pharmaceutical composition and process for preparing the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES362679A1 (es) * 1968-01-19 1971-02-01 Glaxo Lab Ltd Un procedimiento para la preparacion de nuevos esteroides anti-inflamatorios, de la serie del pregnano.
US4478822A (en) * 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
WO1989009057A1 (en) * 1988-03-09 1989-10-05 Alcon Laboratories, Inc. Combination of tobramycin and steroids for topical ophthalmic use
EP0343268A1 (en) * 1988-05-25 1989-11-29 Biogal Gyogyszergyar Pharmaceutical composition and process for preparing the same

Also Published As

Publication number Publication date
JPH07309763A (ja) 1995-11-28
ES2078175B1 (es) 1996-10-16
EP0661055A1 (en) 1995-07-05

Similar Documents

Publication Publication Date Title
ES2079994A1 (es) Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
DK0858328T3 (da) Stabile præparater indeholdende N-propargyl-1-aminoindan
ES2079320A1 (es) Disolucion oftalmica a base de un diclofenaco y tobramicina y sus aplicaciones.
CA2028140A1 (en) Novel bacteriocin compositions for use as enhanced broad range
IL110513A (en) Stabilized pharmaceutical compositions containing bupropion
NZ308293A (en) Antibacterial-wound healing compositions comprising a pyruvate, antioxidant and fatty acids
AU4740893A (en) Stabilized pharmaceutical compositions containing derivatives of vitamins D2 and D3
ES2078175A1 (es) Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.
ES2065846A1 (es) Formulacion farmaceutica a base de un agente antiinflamatorio esteroidico o no esteroidico y un antibiotico pertenciente al grupo de los inhibidores de la adn girasa para su utilizacion topica oftalmica.
MY106109A (en) 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions
GB9424766D0 (en) Pharmaceutical composition
CA2063273A1 (en) Surfactant compositions and methods
GR3036159T3 (en) New compounds and compositions useful as antifungal and antimycobacterial agents.
CA2152998A1 (en) Anti-hyperglycemia pharmaceutical composition
AU7125991A (en) Novel antiulcer substance
ITRM910730A1 (it) Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali.
IL105475A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS
CA2042934A1 (en) Treatment of ocular hypertension with an ocular synergistic combination
IL110011A0 (en) Pharmaceutical compositions for the treatment of schizophrenia
AU2774292A (en) Toiletries composition
CA2361081A1 (en) Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis
CA2042936A1 (en) Treatment of ocular hypertension with a synergistic combination for ophthalmic use
CA2162919A1 (en) Rectal Compositions
AU7533394A (en) Antiacid pharmaceutical composition in the form of a suspension based on sucralphate gel
IE890275L (en) Pharmaceutical composition for 4-aroylimidazol-2-ones

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19931231

Kind code of ref document: B1

Effective date: 19931231

FA2A Application withdrawn

Effective date: 19970317